中国医药人等这一刻太久了中国创新药的热潮还在持续。7月3日,迪哲医药公告称,舒沃哲的新药上市申请正式获得美国食品药品监督管理局(FDA)批准。资料显示,舒沃哲是迪哲医药的首款出海创新药,用于经治EGFR Exon20ins突变型晚期非小细胞肺癌(NSCLC)的成人患者,也是中国首个独立研发在美获批的全球首创新药。一位从事医药创投的人在朋友圈写道:“由于今年的好消息实在太多了,舒沃哲获FDA批准这么...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.